Abemaciclib (LY2835219) , ≥98% , 1231930-82-7
CAS NO.:1231930-82-7
Empirical Formula: C28H36F2N8O3S
Molecular Weight: 602.699
MDL number: MFCD25562906
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB119.20 | In Stock |
|
| 10MG | RMB183.20 | In Stock |
|
| 25MG | RMB351.20 | In Stock |
|
| 50mg | RMB559.20 | In Stock |
|
| 100MG | RMB799.20 | In Stock |
|
| 250mg | RMB1412.80 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| storage temp. | -20° |
| solubility | Soluble in DMSO (up to at least 25 mg/ml) or in Water (up to at least 25 mg/ml). |
| form | solid |
| color | Off-white |
| Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 1 month. |
| CAS DataBase Reference | 1231930-82-7 |
Description and Uses
Abemaciclib (1231930-82-7) is a potent and selective CDK4/6 inhibitor (IC50= 2 nM and 10 nM respectively).1It caused G1 cell cycle arrest in colo-205 colorectal cells, MDA-MB-361 breast cancer cells, and MV4-11 AML cells. Abemaciclib was also active in several human tumor xenograft models. It displayed efficacy in patients with various solid tumors including breast cancer, non-small cell lung cancer. Glioblastoma, melanoma, colorectal cancer, and hormone receptor-positive breast cancer.2Abemaciclib induced a T cell inflamed tumor microenvironment and enhanced the efficacy of PD-L1 checkpoint blockade in MCF-7 breast cancer cells.3FDA approved for the treatment of advanced breast cancers.
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine is an CDK4/6 protein kinase inhibitor with potential antitumor effects.
Safety
| Symbol(GHS) | ![]() GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501 |






